Annual SG&A
$249.75 M
+$22.45 M+9.87%
31 December 2023
Summary:
Royalty Pharma annual selling, general & administrative expenses is currently $249.75 million, with the most recent change of +$22.45 million (+9.87%) on 31 December 2023. During the last 3 years, it has risen by +$68.03 million (+37.44%). RPRX annual SG&A is now at all-time high.RPRX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$56.72 M
+$2.01 M+3.68%
30 September 2024
Summary:
Royalty Pharma quarterly selling, general & administrative expenses is currently $56.72 million, with the most recent change of +$2.01 million (+3.68%) on 30 September 2024. Over the past year, it has dropped by -$514.00 thousand (-0.90%). RPRX quarterly SG&A is now -33.81% below its all-time high of $85.69 million, reached on 31 March 2023.RPRX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$10.09 B
+$630.00 M+6.66%
30 September 2024
Summary:
Royalty Pharma TTM selling, general & administrative expenses is currently $10.09 billion, with the most recent change of +$630.00 million (+6.66%) on 30 September 2024. Over the past year, it has increased by +$9.82 billion (+3724.23%). RPRX TTM SG&A is now at all-time high.RPRX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +9.9% | -0.9% | +3724.2% |
| 3 y3 years | +37.4% | +16.7% | +5300.9% |
| 5 y5 years | +303.4% | +121.5% | +10000.0% |
RPRX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +37.4% | -33.8% | +22.9% | at high | +19.3% |
| 5 y | 5 years | at high | +303.4% | -33.8% | +146.0% | at high | +257.1% |
| alltime | all time | at high | +303.4% | -33.8% | +146.0% | at high | +257.1% |
Royalty Pharma Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $56.72 M(+3.7%) | $228.26 M(-0.2%) |
| June 2024 | - | $54.71 M(-5.1%) | $228.78 M(+3.2%) |
| Mar 2024 | - | $57.65 M(-2.6%) | $221.71 M(-11.2%) |
| Dec 2023 | $249.75 M(+9.9%) | $59.19 M(+3.4%) | $249.75 M(-5.3%) |
| Sept 2023 | - | $57.23 M(+20.2%) | $263.79 M(+2.5%) |
| June 2023 | - | $47.63 M(-44.4%) | $257.25 M(-1.6%) |
| Mar 2023 | - | $85.69 M(+17.0%) | $261.46 M(+15.0%) |
| Dec 2022 | $227.30 M(+24.3%) | $73.23 M(+44.5%) | $227.30 M(+13.5%) |
| Sept 2022 | - | $50.69 M(-2.2%) | $200.24 M(+1.1%) |
| June 2022 | - | $51.84 M(+0.6%) | $198.13 M(+3.6%) |
| Mar 2022 | - | $51.54 M(+11.7%) | $191.21 M(+4.6%) |
| Dec 2021 | $182.83 M | $46.16 M(-5.0%) | $182.83 M(-2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $48.59 M(+8.2%) | $186.78 M(-1.1%) |
| June 2021 | - | $44.92 M(+4.1%) | $188.93 M(+1.1%) |
| Mar 2021 | - | $43.16 M(-13.9%) | $186.81 M(+2.8%) |
| Dec 2020 | $181.72 M(+75.7%) | $50.12 M(-1.2%) | $181.72 M(+17.5%) |
| Sept 2020 | - | $50.73 M(+18.5%) | $154.66 M(+19.4%) |
| June 2020 | - | $42.80 M(+12.4%) | $129.53 M(+10.6%) |
| Mar 2020 | - | $38.06 M(+65.1%) | $117.08 M(+13.2%) |
| Dec 2019 | $103.44 M(+67.1%) | $23.06 M(-9.9%) | $103.44 M(+28.7%) |
| Sept 2019 | - | $25.60 M(-15.6%) | $80.38 M(+46.7%) |
| June 2019 | - | $30.35 M(+24.2%) | $54.77 M(+124.2%) |
| Mar 2019 | - | $24.43 M | $24.43 M |
| Dec 2018 | $61.91 M(-41.8%) | - | - |
| Dec 2017 | $106.44 M | - | - |
FAQ
- What is Royalty Pharma annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Royalty Pharma?
- What is Royalty Pharma annual SG&A year-on-year change?
- What is Royalty Pharma quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Royalty Pharma?
- What is Royalty Pharma quarterly SG&A year-on-year change?
- What is Royalty Pharma TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Royalty Pharma?
- What is Royalty Pharma TTM SG&A year-on-year change?
What is Royalty Pharma annual selling, general & administrative expenses?
The current annual SG&A of RPRX is $249.75 M
What is the all time high annual SG&A for Royalty Pharma?
Royalty Pharma all-time high annual selling, general & administrative expenses is $249.75 M
What is Royalty Pharma annual SG&A year-on-year change?
Over the past year, RPRX annual selling, general & administrative expenses has changed by +$22.45 M (+9.87%)
What is Royalty Pharma quarterly selling, general & administrative expenses?
The current quarterly SG&A of RPRX is $56.72 M
What is the all time high quarterly SG&A for Royalty Pharma?
Royalty Pharma all-time high quarterly selling, general & administrative expenses is $85.69 M
What is Royalty Pharma quarterly SG&A year-on-year change?
Over the past year, RPRX quarterly selling, general & administrative expenses has changed by -$514.00 K (-0.90%)
What is Royalty Pharma TTM selling, general & administrative expenses?
The current TTM SG&A of RPRX is $10.09 B
What is the all time high TTM SG&A for Royalty Pharma?
Royalty Pharma all-time high TTM selling, general & administrative expenses is $263.79 M
What is Royalty Pharma TTM SG&A year-on-year change?
Over the past year, RPRX TTM selling, general & administrative expenses has changed by +$9.82 B (+3724.23%)